FDA Obesity Drug Guidance Should Relax Trial Enrollment Criteria, PhRMA Says
This article was originally published in The Pink Sheet Daily
Executive Summary
Patients with a body mass index exceeding 25, rather than BMI>27, should be allowed in trials, PhRMA says. Revised guidance should also eliminate the need for a weight-loss attempt immediately before enrollment, the association suggests.
You may also be interested in...
Obesity Drug One-Year Data Sufficient For Safety and Efficacy – Cmte
Weight-loss drug trials should include one-year of data on at least 1,500 patients, FDA’s Endocrinologic & Metabolic Drugs Advisory Committee says. Run-in periods prior to clinical trials are unnecessary, committee members agree.
Obesity Drug One-Year Data Sufficient For Safety and Efficacy – Cmte
Weight-loss drug trials should include one-year of data on at least 1,500 patients, FDA’s Endocrinologic & Metabolic Drugs Advisory Committee says. Run-in periods prior to clinical trials are unnecessary, committee members agree.
Bristol Has Appetite For Obesity: Firm To License Solvay Phase I Cannabinoid Antagonist
The companies will jointly develop and commercialize SLV319. Potential inroad into obesity market aligns with Bristol's long-term focus on "high-potential disease areas," company says.